Gene therapy offers hope for toddler with rare genetic disorder in India

A toddler in India has been diagnosed with spinal muscular atrophy (SMA), a rare and progressive genetic disorder that affects motor neurons and muscle control. The condition requires treatment with Zolgensma, a gene therapy that represents one of the most expensive medications globally, with costs reaching approximately Rs 10 crore per treatment course.

The 22-month-old patient, identified as Vedansh, faces a critical window for intervention, as SMA is most effectively treated in its early stages. The child's parents have been unable to meet the substantial financial burden required for the therapy independently, leaving the family searching for alternative solutions.

Social media influencer Mayuresh Gujar and his team have initiated a public campaign to raise awareness and gather support for the child's medical needs. The effort aims to connect the family with potential donors and organizations capable of providing financial assistance for the life-changing treatment.

Spinal muscular atrophy is caused by mutations in the SMN1 gene, leading to progressive muscle weakness and atrophy. Without intervention, SMA can significantly impact a child's ability to walk, eat, and breathe. Zolgensma, approved in several countries including India, has demonstrated remarkable efficacy in halting disease progression and improving outcomes when administered early in the disease course.